High Circulating VEGF Level Predicts Poor Overall Survival in Lung Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2013 Apr 5

PMID 23552871

Citations 12

Authors

Pingping Hu

Weidong Liu

Liguang Wang

Miaomiao Yang

Jiajun Du

Affiliations

Soon will be listed here.

Abstract

Purpose: Vascular endothelial growth factor (VEGF) is considered as the best-validated key regulator of angiogenesis, while the prognostic role of circulating VEGF in lung cancer remains controversial. We conducted a meta-analysis to evaluate the prognostic role of circulating VEGF.

Methods: Nineteen studies with a total number of 2,890 patients were analyzed in our meta-analysis. Hazard ratios (HRs) and their 95 % confidence intervals (CIs) were used to quantify the predictive ability of circulating VEGF on survival.

Results: The pooled HR of all 17 studies evaluating overall survival (OS) was 1.29 (95 % CI 1.19-1.40, p < 0.001), indicating high circulating VEGF predicted poor OS. When grouped by disease stages, the pooled HRs were 0.97 (95 % CI 0.47-1.47, p < 0.001) for operable stage and 1.34 (95 % CI 1.18-1.49, p < 0.001) for inoperable stage. The pooled HRs were 1.28 (95 % CI 1.15-1.42, p < 0.001) for serum and 1.31 (95 % CI 1.13-1.49, p < 0.001) for plasma, when categorized by blood sample. Meta-analysis of circulating VEGF related to progression-free survival (PFS) was performed in 7 studies, and the pooled HR was 1.03 (95 % CI 0.96-1.09).

Conclusions: Our results indicate that high level of circulating VEGF predicts poor OS in lung cancer, yet it does not predict poor PFS.

Citing Articles

Evaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosis.

Feng X, Muller D, Zahed H, Alcala K, Guida F, Smith-Byrne K EBioMedicine. 2023; 92:104623.

PMID: 37236058 PMC: 10232655. DOI: 10.1016/j.ebiom.2023.104623.

Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.

Choi S, Yoo S, Lee S, Park J Arch Pharm Res. 2022; 45(4):263-279.

PMID: 35449345 DOI: 10.1007/s12272-022-01382-6.

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study.

Li X, Huang J, Qiu Y, Zhang Q, Yang S, Wu K Front Pharmacol. 2021; 12:649222.

PMID: 34025415 PMC: 8138310. DOI: 10.3389/fphar.2021.649222.

Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer.

Tian W, Cao C, Shu L, Wu F Onco Targets Ther. 2020; 13:12113-12129.

PMID: 33262610 PMC: 7699985. DOI: 10.2147/OTT.S276150.

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.

Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M Cancers (Basel). 2020; 12(2).

PMID: 32085544 PMC: 7072584. DOI: 10.3390/cancers12020473.

References

Hanrahan E, Ryan A, Mann H, Kennedy S, Langmuir P, Natale R . Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res. 2009; 15(10):3600-9. DOI: 10.1158/1078-0432.CCR-08-2568. View

Donovan L, Sankaridurg P, Ho A, Naduvilath T, Smith 3rd E, Holden B . Myopia progression rates in urban children wearing single-vision spectacles. Optom Vis Sci. 2011; 89(1):27-32. PMC: 3249020. DOI: 10.1097/OPX.0b013e3182357f79. View

Jantus-Lewintre E, Sanmartin E, Sirera R, Blasco A, Sanchez J, Taron M . Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 2011; 74(2):326-31. DOI: 10.1016/j.lungcan.2011.02.016. View

Edelman M, Hodgson L, Wang X, Christenson R, Jewell S, Vokes E . Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. J Thorac Oncol. 2011; 6(11):1902-6. PMC: 5673085. DOI: 10.1097/JTO.0b013e31822a7383. View

Egger M, Schneider M, Junker C, Lengeler C, Antes G . Language bias in randomised controlled trials published in English and German. Lancet. 1997; 350(9074):326-9. DOI: 10.1016/S0140-6736(97)02419-7. View

Kaya A, Ciledag A, Eris Gulbay B, Poyraz B, Celik G, Sen E . The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med. 2004; 98(7):632-6. DOI: 10.1016/j.rmed.2003.12.017. View

Farhat F, Tfayli A, Fakhruddin N, Mahfouz R, Otrock Z, Alameddine R . Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol. 2012; 84(2):149-60. DOI: 10.1016/j.critrevonc.2012.02.012. View

Choi J, Kim H, Lim H, Nam D, Kim H, Yi J . Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer. 2001; 33(2-3):171-9. DOI: 10.1016/s0169-5002(01)00200-8. View

Qu J, Wang M, He H, Tang Y, Ye X . The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Cancer Res Clin Oncol. 2012; 138(5):819-25. DOI: 10.1007/s00432-012-1149-7. View

10.

Lee J, Hong Y, Han C, Hwang D, Hong S . Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?. Int J Oncol. 2000; 17(1):149-52. View

11.

Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M . The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2004; 92(1):131-9. PMC: 2361730. DOI: 10.1038/sj.bjc.6602258. View

12.

Altman D . Systematic reviews of evaluations of prognostic variables. BMJ. 2001; 323(7306):224-8. PMC: 1120839. DOI: 10.1136/bmj.323.7306.224. View

13.

Thurston G, Kitajewski J . VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer. 2008; 99(8):1204-9. PMC: 2570514. DOI: 10.1038/sj.bjc.6604484. View

14.

Brattstrom D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L . Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res. 1998; 18(2A):1123-7. View

15.

Kyzas P, Cunha I, Ioannidis J . Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005; 11(4):1434-40. DOI: 10.1158/1078-0432.CCR-04-1870. View

16.

Hegde P, Jubb A, Chen D, Li N, Meng Y, Bernaards C . Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res. 2012; 19(4):929-37. DOI: 10.1158/1078-0432.CCR-12-2535. View

17.

Young R, Tin A, Brown N, Jitlal M, Lee S, Woll P . Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. Br J Cancer. 2012; 106(6):1153-9. PMC: 3304418. DOI: 10.1038/bjc.2012.50. View

18.

LAKATOS E . Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988; 44(1):229-41. View

19.

Kut C, Gabhann F, Popel A . Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007; 97(7):978-85. PMC: 2360423. DOI: 10.1038/sj.bjc.6603923. View

20.

Mack P, Redman M, Chansky K, Williamson S, Farneth N, Lara Jr P . Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008; 26(29):4771-6. PMC: 2653139. DOI: 10.1200/JCO.2008.17.0662. View